Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell W Jenkins

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Science (New York, N.Y.)|April 9, 2026
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunityJooho Chung, Mounica Vallurupalli, Sarah Noel, et al.
Biorxiv : the Preprint Server for Biology|December 16, 2024
Potent antitumor activity of a designed interleukin-21 mimicJung-Ho Chun, Birkley S Lim, Suyasha Roy, et al.
Science Immunology|September 26, 2025
Design of a potent interleukin-21 mimic for cancer immunotherapyJung-Ho Chun, Birkley S Lim, Suyasha Roy, et al.
Cancer Discovery|November 5, 2017
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell ActivationJiehui Deng, Eric S Wang, Russell W Jenkins, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapyOr-Yam Revach, Angelina M Cicerchia, Ofir Shorer, et al.
Cell|November 3, 2018
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeLivnat Jerby-Arnon, Parin Shah, Michael S Cuoco, et al.
Cell Reports. Medicine|June 27, 2025
Overcoming resistance to immunotherapy by targeting CD38 in human tumor explantsOr-Yam Revach, Angelina M Cicerchia, Ofir Shorer, et al.
Nature|January 12, 2023
Targeting TBK1 to overcome resistance to cancer immunotherapyYi Sun, Or-Yam Revach, Seth Anderson, et al.
Cell|April 23, 2024
DrugMap: A quantitative pan-cancer analysis of cysteine ligandabilityMariko Takahashi, Harrison B Chong, Siwen Zhang, et al.
Cancer Discovery|November 5, 2017
<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor SpheroidsRussell W Jenkins, Amir R Aref, Patrick H Lizotte, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Science (New York, N.Y.)|April 9, 2026
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunityJooho Chung, Mounica Vallurupalli, Sarah Noel, et al.
Biorxiv : the Preprint Server for Biology|December 16, 2024
Potent antitumor activity of a designed interleukin-21 mimicJung-Ho Chun, Birkley S Lim, Suyasha Roy, et al.
Science Immunology|September 26, 2025
Design of a potent interleukin-21 mimic for cancer immunotherapyJung-Ho Chun, Birkley S Lim, Suyasha Roy, et al.
Cancer Discovery|November 5, 2017
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell ActivationJiehui Deng, Eric S Wang, Russell W Jenkins, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapyOr-Yam Revach, Angelina M Cicerchia, Ofir Shorer, et al.
Cell|November 3, 2018
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeLivnat Jerby-Arnon, Parin Shah, Michael S Cuoco, et al.
Cell Reports. Medicine|June 27, 2025
Overcoming resistance to immunotherapy by targeting CD38 in human tumor explantsOr-Yam Revach, Angelina M Cicerchia, Ofir Shorer, et al.
Nature|January 12, 2023
Targeting TBK1 to overcome resistance to cancer immunotherapyYi Sun, Or-Yam Revach, Seth Anderson, et al.
Cell|April 23, 2024
DrugMap: A quantitative pan-cancer analysis of cysteine ligandabilityMariko Takahashi, Harrison B Chong, Siwen Zhang, et al.
Cancer Discovery|November 5, 2017
<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor SpheroidsRussell W Jenkins, Amir R Aref, Patrick H Lizotte, et al.
Pageof 8